Of the 13 patients for whom KRAS sequencing was performed, 4 patients (30.8%) had wild-type KRAS, which is associated with response to anti-EGFR therapy in colorectal cancer [34, 35]. The gene discussed is EGFR; the disease is colorectal cancer.